Physician profile
George Whitney Reader
NPI 1508812744
$4,129.34
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $794 · 2021: $1,443 · 2022: $959 · 2023: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $541.55 | 2019-2023 | Xarelto |
| Amgen INC. | $468.88 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $409.04 | 2020-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $375.22 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $352.38 | 2019-2023 | |
| Abbott Laboratories | $248.79 | 2021-2023 | Amplatzer Amulet |
| Sanofi-Aventis U.S. LLC | $200.03 | 2019-2020 | |
| Esperion Therapeutics, INC. | $181.96 | 2020-2021 | |
| Amarin Pharma, INC. | $176.47 | 2021-2022 | |
| Pfizer INC. | $135.18 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $120.13 | 2019 | |
| United Therapeutics Corporation | $116.76 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $116.63 | 2021-2022 | |
| Boston Scientific Corporation | $77.41 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $71.56 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $71.02 | 2019 | |
| Lundbeck LLC | $54.07 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $51.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.22 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $44.51 | 2020-2022 | |
| Abiomed | $41.47 | 2022 | |
| Bardy Diagnostics, INC. | $34.70 | 2020 | |
| Medtronic Vascular, INC. | $30.60 | 2020 | |
| Cvrx, INC. | $30.43 | 2022-2023 | Barostim Neo System |
| Genzyme Corporation | $18.51 | 2021 | |
| Novo Nordisk INC | $15.66 | 2022 | |
| Edwards Lifesciences Corporation | $14.58 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $14.32 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.81 | 2021 | |
| Surmodics, INC. | $7.11 | 2023 | Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Reader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.